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Abstract 
Aims: This study retrospectively evaluated the clinical impact of brain FDG PET/CT 
performed in selected patients with cognitive impairment at a tertiary referral centre in the 
UK. It also assessed the accuracy of FDG PET/CT to correctly establish the diagnosis of 
$O]KHLPHU¶V'HPHQWLD$'LQDµUHDO-ZRUOG¶FOLQLFDOSUDFWLFH 
Methods and materials: Using an institutional radiology database, a total of 136 patients 
were identified for inclusion in the study. FDG PET/CT was performed using a standard 
technique and interpreted by dual-trained radiologists and nuclear medicine physicians. 
Standardized questionnaires were sent to the referring clinicians to establish the final clinical 
diagnosis and to obtain information about the clinical impact of FDG PET/CT.  
Results: There was a 72% questionnaire return (98/136), with mean patient follow-up of 471 
(SD 205) days. FDG PET/CT had an impact on patient management in 81%, adding 
confidence to the pre-test diagnosis in 43%, changing the pre-test diagnosis in 35%, reducing 
the need for further investigations in 42%, and resulting in a change in therapy in 32%. There 
was substantial correlation between the PET/CT diagnosis and final clinical diagnosis with a 
correlation (k) coefficient of 0.78 (p <0.0001). The accuracy of FDG PET/CT in diagnosis of 
AD was 94% (CI 87-99), with a sensitivity of 87% (CI 75-92) and a specificity of 97% (CI 
87-99). 
Conclusion: FDG PET/CT brain imaging has a significant clinical impact when performed 
selectively in patients with cognitive impairment and shows high accuracy in the diagnosis of 
$'LQDµUHDO-ZRUOG¶FOLQLFDOSUDFWLFH!
$EVWUDFW
Introduction 1 
Dementia is a clinical syndrome characterised by neurodegeneration that leads to progressive 2 
deterioration in various intellectual domains including memory, language and executive brain 3 
function, and usually results in a relentless decline in the capacity for independent living [1]. 4 
7KHFRPPRQHVWFDXVHRIQHXURGHJHQHUDWLYHGHPHQWLDLV$O]KHLPHU¶VGLVHDVH$'5 
accounting for approximately 65% of all cases, followed by vascular dementia, mixed 6 
dementia, Lewy body dementia (DLB), fronto-temporal dementia (FTD), and other rare 7 
causes. The World Alzheimer Report identified that there were 46 million people living with 8 
dementia worldwide in 2015, with a total estimated cost of $818 billion, potentially rising to 9 
$1 trillion by 2018 [2]. In the UK, it was estimated that in 2015, there were over 850,000 10 
people living with dementia, with a total cost to the economy of £26 billion [3]. Although 11 
some recent epidemiological studies have shown that the prevalence of dementia in high-12 
income countries such as the USA and UK may not be rising as historically predicted, it 13 
unambiguously remains a problem of worldwide concern with significant implications for 14 
economic, health and social care provision [4].  15 
 16 
As dementia is an incurable condition, a relatively apathetic approach from medical 17 
professionals, health care planners and even patients has traditionally contributed to delays in 18 
diagnosis. With increasing recognition of the benefits of primary, secondary and tertiary 19 
prevention of cognitive impairment, the role of timely diagnosis is being revisited [5-6]. It is 20 
also well-recognised that in the early stages of the disease, especially in younger patients 21 
(<65 years) and those with atypical presentations, clinical diagnosis can be both challenging 22 
and unreliable [7]. National Institute for Health and Care Excellence (NICE) guidelines state 23 
that conventional neuroimaging with computed tomography (CT) and magnetic resonance 24 
imaging (MRI) should be used in patients with suspected dementia to exclude other 25 
5HYLVHG0DQXVFULSW
 2 
pathologLFDOFRQGLWLRQVRUWRHVWDEOLVKDVXEW\SHRIGHPHQWLDVXFKDV$O]KHLPHU¶VGLVHDVH26 
(AD) or vascular dementia [8]. More recently, the first new guidance for AD diagnosis since 27 
1984 emphasized that functional neuroimaging with [18F]-2-fluoro-2-deoxy-D-glucose (FDG) 28 
positron emission tomography/computed tomography (PET/CT) can be used as a 29 
pathophysiological biomarker of AD by depicting reduced FDG uptake in the brain [9]. In 30 
recognition of the need to improve diagnosis, strategic clinical networks (SCNs) in the UK 31 
have produced specific guidance on the use of conventional and highly specialised neuro-32 
imaging in dementia, which defines the role of FDG PET/CT by judiciously limiting its use 33 
to those cases where the patients are relatively young (<65 years), difficult to diagnose, 34 
and/or when the knowledge of the precise subtype of dementia would likely influence clinical 35 
management (Table 1) [10]. 36 
 37 
Despite the recognition of the utility of FDG PET/CT to diagnose and differentiate between 38 
different subtypes of dementia in appropriate cases [11-14], there is currently a lack of 39 
evidence looking at the clinical impact of FDG brain imaging in dementia from a referring 40 
FOLQLFLDQ¶VSHUVSHFWLYHSDUWLFXODUO\LQD8.SDWLHQWFRKRUW7KLVVWXG\ZDVFRQGXFWHGWR41 
primarily evaluate the clinical impact of FDG PET brain scans in patients with cognitive 42 
impairment, who did not have a clear diagnosis after initial expert assessment and standard 43 
neuro-UDGLRORJLFDOH[DPLQDWLRQVLQDµUHDO-ZRUOG¶FOLQLFDOSUDFWLFH7KHVHFRQGDU\DLPwas to 44 
assess the accuracy, sensitivity and specificity of FDG PET/CT in diagnosing the commonest 45 
cause of neurodegenerative dementia, i.e. AD, when compared with the final clinical 46 
diagnosis, in patients presenting with difficult to diagnose dementia at a single tertiary 47 
referral centre in the UK. 48 
  49 
 3 
Methods and materials 50 
Study population 51 
$UHWURVSHFWLYHUHYLHZRIDSURVSHFWLYHO\PDLQWDLQHGGDWDEDVHDWWKHDXWKRUV¶FHQWUHVKRZHG52 
that a total of 158 patients had undergone brain FDG imaging in a two-year period between 53 
June 2013 to June 2015. The inclusion criteria for the study were as follows: patients who 54 
had undergone brain FDG PET/CT for the evaluation of cognitive impairment, following a 55 
negative brain CT or MRI, and where no specific diagnosis was possible after an expert 56 
assessment by a clinician experienced in managing patients with cognitive impairment and 57 
dementia. Cognitive impairment was defined clinically for the purposes of this clinico-58 
radiological pathway as an identifiable decline in memory, language, thinking and/or 59 
judgement interfering with activities of daily living. There were 22 exclusions, i.e. patients 60 
who had a brain PET/CT scan performed for other indications such as epilepsy or tumour 61 
assessment, with 136 individuals meeting the inclusion criteria for the study.  Patient 62 
demographics including name, age, gender, comorbidities, and the referring physician details 63 
were collected for all patients. PET/CT reports were retrieved retrospectively from the 64 
LQVWLWXWLRQDOFRPSXWHULVHGUDGLRORJ\LQIRUPDWLRQV\VWHP&5,6+HDOWKFDUH6RIWZDUH65 
Solutions, HSS, Mansfield, UK). Institutional ethical approval was not required at the 66 
DXWKRUV¶LQVWLWXWLRQIRUDUHWURVSHFWLYHUHYLHZRIDQH[LVWLQJVWDQdard clinical service, as this 67 
was classified as a service evaluation and quality improvement exercise. 68 
 69 
PET/CT technique 70 
$OO3(7&7H[DPLQDWLRQVZHUHSHUIRUPHGRQD*('LVFRYHU\3(7&7VFDQQHU71 
(General Electric, GE, Healthcare Ltd, Chalfont St Giles, UK). All patients were asked to fast 72 
for a minimum of 6-hours prior to tracer injection. The blood glucose prior to injection was 73 
<10 mmol/l in all cases. A standard injection of 250 (+/- 10%) MBq of FDG was 74 
 4 
administered, followed by a 30-minute uptake period. The PET protocol used a 10-minute 75 
single bed acquisition with the head positioned in an appropriate head restraint. Image 76 
reconstruction parameters were as follows: time-of-IOLJKWDOJRULWKP9XH3RLQW);*(77 
Healthcare), with iterative reconstruction involving 24 subsets, 2 iterations and a 3.2mm 78 
spatial filter. The CT component of the study was performed with the patient in the same 79 
position, using the following parameters: 125 kV, 250 mAs and 3.75 mm slice thickness. 80 
 81 
PET/CT reporting criteria 82 
The clinical report was generated following visual PET data review in transaxial, sagittal and 83 
coronal planes with and without PET/CT LPDJHIXVLRQRQD*($GYDQWDJH Workstation 84 
(GE Healthcare, version 4.5). All cases were dual reported by two of three experienced 85 
consultants who are dual-certificated in clinical radiology and nuclear medicine (with 9-86 
years, 7-years and 5-years of independent reporting experience, respectively). Standard and 87 
accepted reporting criteria were applied in terms of well-recognised patterns of regional 88 
hypometabolism to distinguish between the various causes of cognitive impairment (Table 89 
2). In the case of any discrepancy between the two reporters, a consensus was reached before 90 
issuing the final clinical read-out. The originally issued clinical report for the PET/CT scan 91 
was used for subsequent primary and secondary outcome analysis. 92 
 93 
Questionnaires for assessment of final clinical diagnosis and clinical impact 94 
Questionnaires were sent to the referring physicians. The purpose of the questionnaire was to 95 
establish the final clinical diagnosis, which could be correlated with the suggested diagnosis 96 
IURPWKH3(7&7UHSRUW2WKHULQIRUPDWLRQVXFKDVWKHUHIHUULQJSK\VLFLDQ¶VVSHFLDOW\DQG97 
questions about the usefulness of the PET/CT report was probed. A Likert scale (1-5) was 98 
used to find out how useful the referrer found the PET/CT report for each patient. Following 99 
 5 
this, a polar question was asked to see whether the PET/CT scan had an impact on clinical 100 
management. If it did, further questions were asked to assess how it had an impact on clinical 101 
management, which were the following:  102 
? Did the PET/CT result add confidence to the pre-test diagnosis?  103 
? Did the PET/CT result change the pre-test clinical diagnosis?  104 
? Did the PET/CT result reduce the need for further investigations? 105 
? Did the PET/CT result lead to a change in therapy?  106 
 107 
Statistical analysis 108 
All subjects were included in the analysis using the intent-to-treat principle. Statistical 109 
analyses were performed using SPSS version 22.0 (IBM, Chicago, IL, USA). The 110 
concordance between the final clinical diagnosis and the diagnoses derived from the initial 111 
PET/CT report was analysed using the kappa (k) correlation coefficient. The range of 112 
plausible values for kappa were between 0 and 1 (k<0.20 = poor agreement, 0.21<k<0.40 = 113 
fair agreement, 0.41<k<0.60 = moderate agreement, 0.61<k<0.80 = substantial agreement, 114 
and 0.81<k<1.00 = almost perfect agreement). Contingency tables were used to calculate 115 
sensitivity, specificity and accuracy of FDG PET/CT for the diagnosis of AD. The final 116 
clinical diagnosis was used as the reference standard for these calculations. P-values of <0.05 117 
or 95% confidence intervals (95% CI) that did not include 1.0 were considered to be 118 
statistically significant. 119 
  120 
 6 
Results 121 
A total of 136 patients were included in this retrospective study and there were 72 males 122 
(53%) and 64 females (47%). The age range was 33 to 88 years with the mean age of males 123 
being 64 years (SD 11.8) and females being 66 years (SD 9.9). Referrals were received from 124 
four clinical specialties (psychiatry for the elderly, neurology, general psychiatry and care of 125 
the elderly) (Figure 1). In total, there were 42 individuals with a PET/CT diagnosis of AD, 126 
11 with FTD, 4 with rarer dementias, 1 individual each had a diagnosis of DLB and mixed 127 
dementia, and 77 patients had a normal scan with no supportive features of neurodegenerative 128 
disease (Figure 2). 129 
 130 
The completed questionnaire response rate was 72% (98/136), with mean patient follow-up 131 
of 471 (SD 205) days. Referring physicians found the PET/CT report useful or very useful in 132 
78% (77/98) of patients. A more objective question showed that in 81% (79/98) the PET/CT 133 
report had an impact on clinical management. In 42 individuals (43%), PET/CT added 134 
confidence to the pre-test clinical diagnosis and in 34 individuals (35%) it changed the pre-135 
test clinical diagnosis. In 41 cases (42%), PET/CT reduced the need for further investigations. 136 
For 31 individuals (32%), the PET/CT report led to a change in therapy. Figure 3 137 
VXPPDULVHVWKHUHIHUULQJSK\VLFLDQV¶UHVSRQVHVWRWKHTXHVWLRQQDLUH 138 
 139 
Of the 98 patients with a confirmed final clinical diagnosis, there was substantial agreement 140 
with the diagnosis suggested by the PET/CT report with a kappa coefficient of 0.78 (p-value 141 
<0.0001) (Figure 4 and 5). There were 14 cases (14/98, 14%) where there was discordance 142 
between the final clinical and PET/CT diagnosis. Eleven of these were µIDOVH-QHJDWLYH¶FDVHV143 
with normal FDG PET/CT findings, where the final clinical diagnosis was given as FTD 144 
(5/11), AD (4/11), and one each of rare dementia (progressive supranuclear palsy) and mixed 145 
 7 
dementia. There was one case with abnormal FDG imaging findings that could not be 146 
definitively classified into a specific dementia sub-type (clinically diagnosed as FTD), one 147 
case which was classified as a sub-type of FTD (logopenic variant primary progressive 148 
aphasia, PPA) but was subsequently clinically diagnosed as a linguistic-variant type of AD 149 
(Figure 6), and only one µIDOVH-SRVLWLYH¶case that was reported as possible early AD where 150 
WKHSDWLHQW¶VFRJQLWLYHIXQFWLRQVXEVHTXHQWO\LPSURYHGDQGDQHXURGHJHQHUDWLYHFDXVHZDV151 
ruled out clinically. The discrepant cases are summarised in table 3. In the 42/98 (43%) cases 152 
that had normal FDG imaging, the diagnosis remained uncertain in 12/42 (29%), and the 153 
commonest final diagnoses included psychiatric disorders in 10/42 (24%), mild cognitive 154 
impairment in 8/42 (19%), and vascular dementia in 7/42 cases (17%). For the diagnosis of 155 
AD, using the final clinical diagnosis as the reference standard, FDG PET/CT had a 156 
sensitivity of 87% (95% CI 75-92), specificity of 97% (95% CI 87-99), positive predictive 157 
value of 93% (95% CI 80-99), and a negative predictive value of 91% (95% CI 83-95). The 158 
overall accuracy of FDG PET/CT in the diagnosis of AD was 94% (95% CI 87-99) (Figure 159 
7). 160 
  161 
 8 
Discussion 162 
The diagnosis of dementia can be challenging, especially in the early stages of the disease, in 163 
younger patients (<65 years), in those with atypical presentations, and in patients with 164 
substantial psychological overlay [1-2]. It is clear from several longitudinal studies that 165 
pathologically proven AD can present with a range of atypical cognitive symptoms and it is 166 
not surprising therefore that clinical diagnosis can have an accuracy of less than 70%, and up 167 
to 50% of patients can remain undiagnosed until a late stage of the disease [1-2, 15]. 168 
Obtaining a timely diagnosis of dementia is important not only in order to allow access to 169 
appropriate treatment, but also to enable individuals with dementia, as well as their families, 170 
to participate more actively in management decisions, plan for their future, and access 171 
support services from statutory and voluntary organisations [5-6]. Failure to make a timely 172 
diagnosis can often lead to a lengthy period of follow-up and prolonged and/or repeated 173 
neuropsychology assessments, which in the long run can prove expensive, while also 174 
generating uncertainty and anxiety for the patient. Identification of the correct sub-type of 175 
dementia is crucial as management, course of disease and prognosis vary considerably 176 
between the different aetiologies [1-2]. It follows that non-invasive imaging tests that not 177 
only corroborate a suspected diagnosis of neurodegenerative dementia, e.g. AD, but also 178 
exclude it with a high level of certainty are needed in these challenging cases.  179 
 180 
The role of neuro-imaging in dementia has traditionally been to exclude structural causes, e.g. 181 
space-occupying lesions and vascular disease. Modern AD imaging guidelines, however, 182 
have changed the emphasis of neuro-imaging to a more effective role in identifying dementia 183 
sub-types by recognising volumetric MRI, FDG PET and amyloid PET imaging as important 184 
imaging biomarkers of the condition [9].   185 
 186 
 9 
The brain is an obligate glucose user for its metabolic requirements, and glycolytic metabolic 187 
activity has been shown to correlate effectively with neuronal and synaptic function [16]. 188 
FDG brain imaging is an in vivo non-invasive test that can, therefore, demonstrate cerebral 189 
glycolytic metabolism as a surrogate marker of synaptic function and neuronal density, which 190 
are invariably reduced in neurodegenerative conditions. This is so much the case that FDG 191 
imaging in AD has sometimes been referred to as the µPHWDEROLFVLJQDWXUH¶RIthe condition 192 
[14]. In the classical case, this manifests as a regional pattern of glucose hypometabolism that 193 
is demonstrated in the parieto-temporal regions, including the precuneus, with additional 194 
reduction in FDG uptake in the posterior cingulate gyri. The posterior cingulate and 195 
precuneus regions are often affected in the earliest stages of AD [11]. The involvement of 196 
these areas, with regional parieto-temporal hypometabolism, with lesser degree of 197 
abnormality in the frontal cortex, and sparing of the primary visual cortex, sensorimotor 198 
cortex, basal ganglia and cerebellum effectively defines the µmetabolic phenotype¶ of AD. 199 
Interestingly, as normal glucose metabolism in the hippocampal structures is less than that in 200 
the neocortex, small reductions in metabolic activity in the hippocampus are not usually 201 
demonstrable on FDG PET in the early stages of the AD [13]. 202 
 203 
The limited ability of morphological imaging to distinguish between different dementia 204 
subtypes is well recognised, as atrophy is often a late sign of the disease [14]. FDG is 205 
currently the most widely available imaging biomarker for dementia diagnosis. Over the last 206 
decade, convincing evidence has emerged to demonstrate that FDG PET imaging has a 15-207 
20% increment in diagnostic accuracy in AD over the traditional nuclear medicine test of 208 
brain perfusion single-photon emission computed tomography (SPECT) [16]. In one of the 209 
few high quality head-to-KHDGFRPSDULVRQVEHWZHHQWKHWZRWHFKQLTXHV2¶%ULHQDQG210 
colleagues [17] showed in a cohort of 98 patients (including 30 control patients) that in 211 
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differentiating healthy patients from those with dementia, FDG PET had a sensitivity of 85% 212 
(95% CI 0.75±0.93) and a specificity of 90% (95% CI, 0.73±0.98), whereas SPECT had 213 
sensitivity of 71% (95% CI 0.58±0.81) and specificity of 70% (95% CI, 0.51±0.85). In 214 
addition to greater diagnostic accuracy, there are other convincing practical reasons why PET 215 
is increasingly replacing SPECT as the functional imaging test of choice in these patients, 216 
including superior spatial resolution, less technical variation and shorter acquisition times. 217 
 218 
Although there have been multiple studies evaluating the accuracy of FDG PET in 219 
diagnosing dementia and identifying its sub-types, there have been very few studies that have 220 
evaluated the actual clinical impact of undertaking FDG PET in patients with an uncertain 221 
diagnosis of dementia. In a retrospective study of 94 patients presenting to a memory clinic 222 
with cognitive impairment and unclear diagnosis who had a PET and were followed up at 5-223 
months and 18-months, La Force et al [18] showed that PET was associated with a definable 224 
impact on management in 56%, with a change in diagnosis in 29%, confirmation of clinician 225 
diagnosis in 16% and had no impact in 28%. In comparison, in the current study conducted in 226 
DµUHDOZRUOG¶FOLQLFDO3(7VHUYLFHLQWKH8.LWZDVVKRZQWKDW)'*3(7&7OHGWRDchange 227 
in the pre-test clinical diagnosis in 35%, obviated the need for further investigations in 42%, 228 
led to a change in therapy in 32%, and overall, had an impact on clinical management in 229 
81%, thereby indicating a substantial clinical utility of FDG imaging in selected patients with 230 
difficult to diagnose dementia. 231 
 232 
There have been a number of studies over the last 15-years that have evaluated the accuracy 233 
of FDG imaging in the diagnosis of AD. For instance, Silverman et al, in one of the largest 234 
multicentre studies of FDG PET imaging of AD in 284 patients, showed that PET had a 235 
sensitivity, specificity and accuracy of 95%, 71% and 89%, respectively [19]. 236 
 11 
Understandably, many of these studies have involved heterogeneous patient cohorts, used 237 
diverse inclusion criteria and applied different interpretative methodology, making direct 238 
comparisons challenging. In order to mitigate against such factors, Bohnen et al applied more 239 
stringent criteria which led to the inclusion of 11 suitable studies of FDG PET in the 240 
diagnosis of AD in their review, which showed that the accuracy of FDG imaging in AD 241 
ranged widely from 68-100% depending on the patient cohort studied, with a large meta-242 
analysis of FDG PET accuracy in AD showing a sensitivity of 86% (CI 76-93) and specificity 243 
of 86% (CI 72-93) [16,20]. In the current practical study, it has been confirmed that it is 244 
possible to achieve a high level of accuracy (94%, CI 87-99) for correctly diagnosing AD 245 
using FDG imaging in a highly selected, relatively young patient population, referred by 246 
specialists in dementia care who were unable to find a definite cause for cognitive 247 
impairment after thorough clinical evaluation and conventional neuro-imaging. 248 
 249 
It is intuitively recognised that patients referred for a complex diagnostic imaging study for 250 
dementia may have a mixture of causal pathological factors, and this can make interpretation 251 
of FDG studies more challenging when these are undertaken in a highly selected patient 252 
cohort [14-15, 21]. This was evident in the current study, where there was a discrepancy 253 
between the PET/CT classification and the final clinical diagnosis in 14 patients (14/98, 254 
14%),QWHUHVWLQJO\WKHPDMRULW\RIWKHVHFDVHVZHUHLQIDFWµIDOVH-QHJDWLYH¶RQ)'*255 
imaging, with a final diagnosis of FTD and AD in five and four cases, respectively. The value 256 
of FDG PET extends beyond the differential diagnosis of dementia by providing valuable 257 
information about cortical metabolic status. Although a completely normal FDG PET scan 258 
does not exclude a diagnosis of dementia, it provides reassuring prognostic information that 259 
cognitive function is likely to remain stable for several years after a normal study, e.g. a mean 260 
follow-up period of 3 years [19]. Herholz and colleagues also showed in a prospective 261 
 12 
longitudinal study of 186 subjects with possible or probable AD that in patients with mild 262 
cognitive deficit and a highly abnormal FDG scan at entry into the study, there was almost a 263 
five-fold risk of disease progression compared to those with mild metabolic deficit or a 264 
normal study [22]. In the relatively small number of suspected AD cases, in a selected and 265 
younger patient cohort, who have a normal or equivocal FDG scan at presentation, it may be 266 
necessary to pursue a definitive diagnosis, especially if they have progressive symptoms. 267 
There is almost certainly a role for the more sensitive amyloid plaque tracers such as 268 
Florbetapir-18F, Florbetaben-F18, and Flutemetamol-F18 in such patients [23-25]. For 269 
instance, in a pivotal study of 59 end-of-life patients, Clark et al compared in vivo amyloid 270 
plaque imaging using Florbetapir-18F to post-PRUWHPHYLGHQFHRIȕ-amyloid neuritic plaque 271 
density [23]. Florbetapir 18F-PET showed a sensitivity and specificity of 92% (CI 78-98) and 272 
100% (CI 80-100), respectively, in detecting the presence of amyloid plaques. These tracers 273 
are now approved for clinical use, and their rational utilisation in highly selected patient 274 
groups is advocated by evidence-based guidelines [26]. TKHDXWKRUV¶SURSRVHGDOJRULWKPIRU275 
the evidence-based and rational use of functional imaging in patients with unexplained 276 
cognitive impairment and/or suspected dementia is shown in Figure 8. 277 
 278 
Diagnostic challenge can also arise in phenotypical variants of AD, which are often referred 279 
WRDVµDW\SLFDO$'¶>@7KHVHSDWLHQWVFDQpresent with focal cortical syndromes, e.g. frontal 280 
variant AD and logopenic aphasia, without the classical amnestic symptoms of AD, and there 281 
can be overlap with FTD both in terms of clinical assessment and functional imaging deficits 282 
on FDG PET. Up to 10% of patients presenting with either AD or FTD on initial clinical 283 
assessment can fall into this particularly challenging group [21]. Furthermore, although FTD 284 
is a relatively rare cause of neurodegenerative dementia overall, affecting 4-15 per 100 000 285 
<65 years, it is often disproportionately over-represented in the cohort of patients who 286 
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encounter diagnostic difficulty and hence are referred for further complex testing [27-28].  287 
Foster et al showed in a study of 45 patients with pathologically proven AD (n=31) and FTD 288 
(n=14) that if utilized in conjunction with clinical evaluation, FDG PET had an accuracy of 289 
89.6%, sensitivity of 86% and specificity of 97.6% and in correctly distinguishing between 290 
the two conditions, whereas clinical accuracy alone was 79% [29]. However, 16% of the 291 
scans were rated as normal or non-diagnostic even in patients with pathologically proven 292 
dementia. FTD is a clinically and pathologically complex disease, with several clinical 293 
variants that include behavioural variant (bv) FTD, semantic dementia, and primary 294 
progressive aphasia (PPA), which itself can be further sub-divided into progressive non-295 
fluent aphasia and logopenic variants [27-28]. It is unsurprising, therefore, that FDG imaging 296 
may be unreliable in accurately determining the cause of dementia in such complex cases. 297 
Moreover, Kipps and co-workers who evaluated 24 patients with a confirmed clinical 298 
diagnosis of behavioural variant (bv) FTD showed that in 7 (29%) cases, there was no MRI 299 
or PET abnormality [30]. They speculated that some of these may in fact UHSUHVHQWµIDOVH-300 
SRVLWLYH¶FOLQLFDOGLDJQRVLV UDWKHUWKDQµIDOVH-QHJDWLYH¶LPDJLQJGLDJQRVLVLHa non-301 
neurodegenerative phenocopy of bvFTD, and advised caution in making the diagnosis in such 302 
cases and recommended careful longitudinal clinical review.  303 
 304 
A significant number of patients in the current study had a final clinical diagnosis of a 305 
psychiatric disorder (24% of those with a normal FDG scan), and 61% of patients were 306 
referred from specialist psychiatric services. It was recognised as early as 1883 that major 307 
affective disorder could lead to reversible cognitive impairment, historically referred to as 308 
µSVHXGR-GHPHQWLD¶ [31]. Although this term has certainly fallen into disfavour over recent 309 
years, as a more thorough description of cognitive deficits associated with various clinical 310 
presentations is preferable, the distinction between functionally related cognitive deficits and 311 
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those hastened by neurodegenerative disease can be particularly challenging in the elderly. 312 
Misdiagnosis between psychiatric disorders and bvFTD may occur, as some of the 313 
symptomatology in bvFTD can be difficult to distinguish from major depressive and 314 
obsessive-compulsive disorders [28]. Also, depressive symptoms may also co-exist in up to 315 
40% of patients with neurodegenerative dementia, further adding to the diagnostic dilemma 316 
[31]. The present study shows that FDG imaging can be very valuable in such patients by 317 
providing supportive evidence of the presence or absence of neurodegenerative dementia, 318 
with the proviso that a negative FDG scan does not completely exclude this diagnosis.  319 
 320 
Some limitations of this study should be acknowledged. This is a single-centre study, the 321 
results of which may not necessarily be applicable in all centres. The retrospective nature of 322 
data collection may have led to some post-WHVWELDVLQFOLQLFLDQV¶UHVSonses and meant that 323 
some data records were incomplete, e.g. it was not possible to obtain objective assessments of 324 
the degree of cognitive impairment in all cases. Semi-quantification or statistical mapping 325 
using semi-analytical software was not used in this study, which instead relied on the clinical 326 
read-out generated by experienced dual-trained radiologists and nuclear medicine physicians. 327 
Finally, there was no post-mortem confirmation of the diagnosis, with exclusive reliance on 328 
the final clinical diagnosis from a case notes review and questionnaire response. The presence 329 
at post-mortem of intra-QHXURQDOQHXURILEULOODU\WDQJOHVFRPSRVHGRIĲ-protein and extra-330 
neuronal neuritic plaques with amyloid-ȕGHSRVLWLRQDUHFRQVLGHUHGWKHKDOOPDUNRI$' It 331 
was understandably not possible in a retrospective study of this nature to obtain a 332 
pathological diagnosis. However, this was mitigated by the strengths of the study in that the 333 
final clinical diagnosis was formulated by an experienced multidisciplinary team of clinicians 334 
after a reasonable longitudinal clinical follow-up of 471 (SD 205) days. 335 
 336 
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,QFRQFOXVLRQWKLVµUHDO-ZRUOG¶VWXG\LQWRWKHXVHRI)'*3(7&7EUDLQLPDJLQJLQD337 
selected patient population in the UK with difficult to diagnose dementia shows that FDG 338 
scans had a significant impact on clinical management in >80% of cases. There was a high 339 
correlation between the PET/CT classification and final clinical diagnosis, with a kappa of 340 
0.78 (p-value <0.0001), and a high accuracy of 94% (95% CI 87-99) for the diagnosis of the 341 
commonest cause of neurodegenerative dementia, AD. It may be possible to improve the 342 
sensitivity of functional imaging for the condition further by utilising newer techniques like 343 
amyloid plaque tracer imaging in a younger patient cohort where FDG imaging is normal or 344 
equivocal, as this does not exclude the diagnosis, and further studies could also evaluate the 345 
effect of semi-quantification of FDG uptake by statistical mapping software on the accuracy 346 
of scan interpretation. It is clear from this study, however, that the added clarity that FDG 347 
PET imaging provides, by either confirming a diagnosis of neurodegenerative dementia and 348 
allowing the patient to access support, treatment and relevant services earlier, or providing 349 
reassurance that it does not appear to be a neurodegenerative disorder, is of great value in 350 
clinical practice. Future studies could attempt to capture the patient experience, and evaluate 351 
the benefits of timely diagnosis, or reassurance, from the patient perspective. 352 
  353 
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Table and figure legends 444 
Table 1 - Clinical scenarios where FDG PET/CT brain imaging would be indicated in the 445 
context of cognitive impairment. 446 
 447 
Table 2 ± Summary of the recognised patterns of metabolic deficit in the main dementia 448 
sub-types. 449 
 450 
Table 3 ± Summary of cases with diagnostic discrepancy between FDG PET/CT findings 451 
and final clinical diagnosis. 452 
 453 
Figure 1 ± Clinical specialties from which patients were referred for brain FDG PET/CT 454 
for evaluation of unexplained cognitive impairment after negative structural imaging 455 
(N=136). 456 
 457 
Figure 2 ± FDG PET/CT diagnoses in patients referred for brain FDG PET/CT for 458 
evaluation of unexplained cognitive impairment after negative structural imaging 459 
(N=136). 460 
 461 
Figure 3 ± Response to questionnaire exploring clinical impact of FDG PET/CT brain 462 
imaging (N=98/136). 463 
 464 
Figure 4 ± 66-year old with a 2-year history of cognitive decline and non-fluent aphasia. 465 
The pre-test diagnosis was uncertain, favouring fronto-temporal dementia (FTD) over 466 
$O]KHLPHU¶V'LVHDVH$'6HOHFWHGLPDJHVDUHVKRZQ$D[LDO)'*3(7B) sagittal 467 
FDG PET, (C) axial unenhanced CT, and (D) axial fused PET/CT. There is symmetric 468 
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hypometabolism in both parietal lobes, involving the posterior cingulate gyri (A, arrows) 469 
and precuneus (B, arrow). These are classical findings of AD. Note the absence of any 470 
atrophy on the unenhanced CT (C). The patient was commenced on anticholinesterase 471 
inhibitor (AChEI) treatment with a good therapeutic response over the next 2-years. 472 
 473 
Figure 5 ± 46-year-old with suspected behavioural variant fronto-temporal dementia 474 
(FTD). Selected images are shown: (A) axial FDG PET, (B) sagittal FDG PET, (C) axial 475 
unenhanced CT, and (D) axial fused PET/CT. There is regional hypometabolism in both 476 
frontal lobes, involving the anterior cingulate gyri bilaterally (A and B, arrows). Note the 477 
absence of any atrophy on the unenhanced CT (C). The FDG imaging findings were 478 
concordant with the clinical suspicion of FTD, giving greater confidence to the final 479 
clinical diagnosis. 480 
 481 
Figure 6 ± 77-year-old with progressive language disorder, dysphasia and mild memory 482 
impairment. The pre-test diagnosis was suspected primary progressive aphasia (PPA) 483 
variant of fronto-temporal dementia (FTD). Selected images are shown: (A) axial FDG 484 
PET, (B) sagittal FDG PET, (C) axial unenhanced CT, and (D) axial fused PET/CT. 485 
There is moderate asymmetric hypometabolism in the left frontal and parietal lobes, with 486 
more mild reduction in metabolic activity within the right parietal cortex (A, arrows). The 487 
left hemispheric defect is shown in the sagittal image (B, arrow). Note the striking 488 
absence of any atrophy on the unenhanced CT, despite moderately severe metabolic 489 
deficits (C). It was felt on the FDG imaging that the appearances were consistent with 490 
logopenic variant PPA. However, the final clinical diagnosis was linguistic-variant 491 
$O]KHLPHU¶VGLVHDVHAD). 492 
 493 
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Figure 7 - Receiver operating characteristic (ROC) curve showing graphically the 494 
accuracy of the FDG PET/CT diagnosis of AD. The area under the curve (AUC) for AD 495 
is 0.94 (95% CI of 0.87-0.99). 496 
 497 
Figure 8 ± A proposed simplified algorithm for the evidence-based and rational use of 498 
functional imaging in patients with unexplained cognitive impairment with negative 499 
conventional imaging and no definite diagnosis after expert clinical assessment.  500 
Note: the algorithm assumes that a diagnosis of vascular dementia will be made on 501 
clinical grounds and using structural imaging ± FDG PET/CT has no role in diagnosing 502 
this condition. If the history or signs suggest additional uncertain aetiology, i.e. mixed 503 
dementia, then pursue as per algorithm. Abbreviations: DLB, dementia with Lewy 504 
bodies; DaTSCANGRSDPLQHDFWLYHWUDQVSRUWHUVFDQ$'$O]KHLPHU¶VGLVHDVH)7'505 
fronto-temporal dementia. 506 
)LJXUH &OLFNKHUHWRGRZQORDG)LJXUH)LJXUHWLII
)LJXUH &OLFNKHUHWRGRZQORDG)LJXUH)LJXUHWLI
)LJXUH &OLFNKHUHWRGRZQORDG)LJXUH)LJXUHJUH\VFDOHWLI
)LJXUH &OLFNKHUHWRGRZQORDG)LJXUH)LJXUHWLI
)LJXUH &OLFNKHUHWRGRZQORDG)LJXUH)LJXUHWLI
)LJXUH &OLFNKHUHWRGRZQORDG)LJXUH)LJXUHWLI
)LJXUH &OLFNKHUHWRGRZQORDG)LJXUH)LJXUHWLI
)LJXUH &OLFNKHUHWRGRZQORDG)LJXUH)LJXUHWLII
Table 1: Clinical scenarios where FDG PET/CT brain imaging would be indicated in the context of cognitive impairment 
 
? Diagnostic difficulty after history, clinical assessment, structural imaging, and formal cognitive testing!
!
? Early onset dementia (<65 years)!
!
? Clinical uncertainty about subtyping of dementia- especially, differentiating AD and FTD!
!
? Atypical presentation of AD or FTD 
 
? Multiple established psychiatric co-morbidities (depression, schizophrenia, bipolar illness, alcohol-related, learning difficulties) with co-
existing and/or new onset cognitive impairment!
!
? Inconclusive formal neuro-psychological assessment!
!
5HYLVHG7DEOH
Table 2: Summary of the recognised patterns of metabolic deficit in the main dementia sub-types * 
 
Dementia 
sub-type 
Typical functional deficits Relative sparing Additional observations 
AD Posterior cingulate gyrus, precuneus, posterior temporal, 
posterior parietal. Initial deficits may be asymmetric.  
Peri-rolandic sensorimotor 
cortex, basal ganglia, cerebellum 
Later deficits - frontal lobes 
FTD ? Classic bvFTD ± frontal and anterior temporal 
cortex, anterior cingulate gyrus. 
? Semantic dementia ± anterior temporal deficit 
predominates, often asymmetric 
? lvPPA ± left-dominant posterior temporal and 
parietal 
? naPPA ± inferior frontal, temporo-parietal 
junction and left peri-Rolandic gyri 
Visual cortex ? lvPPA ± overlap with AD 
? naPPA ± overlap with 
atypical Parkinsonism and 
MND 
DLB Bilateral parietal and posterior temporal (similar to AD), 
occipital (usually spared in AD) 
Less sparing of visual cortex Abnormal DaTSCAN 
CBGD Asymmetric sensorimotor cortex, fronto-parietal, basal 
ganglia (caudate and putamen), thalamus 
 Abnormal DaTSCAN 
PSP Mid-brain, caudate, lateral and medial frontal lobes  Abnormal DaTSCAN 
PD-related 
dementia 
Similar to AD More mesiotemporal and less 
visual cortex sparing 
Abnormal DaTSCAN 
 
Key: $' $O]KHLPHU¶V'LVHDVH)7' )URQWR-temporal dementia; bv= behavioural variant; lvPPA = logopenic variant primary progressive 
aphasia; na = non-fluent agrammatic; MND= motor neuron disease; DLB= dementia with Lewy bodies; CBGD= Corticobasal ganglionic 
GHJHQHUDWLRQ363 SURJUHVVLYHVXSUDQXFOHDUSDOV\3' 3DUNLQVRQ¶VGLVHDVH'D76&$1= dopamine active transporter scan (Ioflupane 123I). 
 
 
* Adapted from various sources, including references 12 and 13. 
 
5HYLVHG7DEOH
Table 3: Summary of cases with diagnostic discrepancy between FDG PET/CT findings and final clinical diagnosis 
 
Pt Age Gender Clinical presentation Referral 
source 
FDG imaging diagnosis Final clinical 
diagnosis 
Follow-up 
period 
(Days) 
1 55 M Behavioural disorder, 
mild memory 
impairment 
Neurology AD - mild symmetric parietal 
hypometabolism 
Normal 560 
2 77 M Behavioural disorder Neurology Atypical AD - asymmetric left 
temporal, posterior parietal and frontal 
hypometabolism 
FTD 623 
3 67 M Atypical presentation 
with Parkinsonism and 
language difficulty 
Neurology Normal Progressive 
supranuclear palsy 
567 
4 74 M Memory impairment for 
3 years 
Psychiatry for 
the elderly 
Normal AD 511 
5 59 M Behavioural disorder, 
mild memory 
impairment 
Adult 
psychiatry 
Normal FTD 434 
6 78 F Memory impairment, 
low mood 
Psychiatry for 
the elderly 
Normal Mixed Dementia 427 
7 63 M Behavioural disorder, 
mild memory 
impairment 
Adult 
psychiatry 
Normal FTD 518 
8 51 F Deteriorating cognitive 
function 
Neurology Normal AD 588 
9 41 M Behavioural disorder, 
deteriorating cognitive 
function 
Adult 
psychiatry 
No specific diagnosis ± asymmetric 
left parieto-temporal hypometabolism 
and atrophy 
FTD 224 
10 89 M Cognitive decline, 
behavioural disorder 
Psychiatry for 
the elderly 
Normal AD 527 
11 70 M Treatment-resistant Adult Normal FTD 731 
5HYLVHG7DEOH
recurrent depressive 
disorder 
psychiatry 
12 67 M Cognitive impairment Psychiatry for 
the elderly 
Normal FTD 539 
13 55 M Short-term memory 
deficit, language 
difficulties 
Neurology Normal FTD 679 
14 54 M Cognitive impairment, 
word-finding 
difficulties 
Neurology Normal AD 624 
 
.H\$' $O]KHLPHU¶V'LVHDVH)7' IURQWR-temporal dementia; M= male; F= female. 
!
!
Highlights  
!
1. Dementia remains a problem of worldwide concern with significant implications for 
economic, health and social care provision. 
2. The timely diagnosis of dementia allows patients to benefit from access to appropriate 
treatment, and allows them to be actively engaged in management decisions. 
3. Clinical diagnosis of dementia can be challenging in some patients (young onset, atypical 
presentation and significant psychological overlay). 
4. FDG PET/CT is an important diagnostic tool in these patients. 
5. In this study, FDG PET/CT had an impact on management in >80% of these patients and an 
DFFXUDF\RIIRUWKHGLDJQRVLVRI$O]KHLPHU¶V'LVHDVH 
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